NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market Tuesday that its first quarter revenues rose 4 percent year over year, falling short of the consensus Wall Street estimate.

The company's total revenue for the three months ended March 31 was $84.0 million, compared with $80.9 million in the first quarter of 2016, mainly supported by growing prostate cancer and international test sales. Analysts had predicted revenues of $86.2 million on average.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.